Background: Paper III identified SIRT1-PGC-1α as an upstream convergence point for mitochondrial restorationin Long COVID. This paper extends the analysis downstream, identifying Dynamin-related protein 1 (Drp1) as theexecution hub for mitochondrial fission—the final common pathway in Long COVID mitochondrial fragmentation. Discovery: The Sovereign Discovery Engine (5,179 triplets from 164 papers) identified five mechanistically distinctinterventions converging on Drp1 inhibition: (1) Vitamin K2—rescuing PINK1 deficiency as mitochondrial electroncarrier; (2) GDF15 pretreatment—AMPK activation blocking Drp1; (3) Hemin-MSC-EXO—delivering miR-183-5pto suppress HMGB1/ERK/Drp1; (4) Supersulfides—directly blocking Drp1-Filamin complex formation; (5) EGCG—inhibiting Drp1-mediated fission. Key Finding: Vitamin K2 acts as a mitochondrial electron carrier that rescues PINK1 pathway deficiency.Combined with the Long COVID trial showing symptom improvement with K2/D3 supplementation, this positionsVitamin K2 as a novel therapeutic candidate operating through mitochondrial quality control. Significance: Where Paper III addressed SIRT1-PGC-1α (upstream regulation), this paper targets Drp1 (downstreamexecution). Together, they define a complete therapeutic framework: restore mitochondrial biogenesis ANDprevent pathological fission.
David Tom Foss (Wed,) studied this question.